ClinicaliQ Trial Snapshot
- Optimizing Reperfusion to Improve Outcomes and Neurologic Function — Recruiting • Phase II • Cardiology / Cardiovascular • NCT06990867.
- What is being tested: JX10, a novel therapeutic agent, is being evaluated against placebo in acute ischemic stroke patients to assess its safety and efficacy in improving neurological outcomes and reperfusion.
- Patient eligibility overview: The trial enrolls patients with acute ischemic stroke presenting 4.5 to 24 hours from symptom onset, extending beyond the standard thrombolytic window and potentially capturing patients who would otherwise have limited treatment options.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1. JX10 improves functional outcomes as measured by the modified Rankin Scale score when compared with placebo following AIS. 2. Risk of symptomatic intracranial hemorrhage of JX10 in participants with AIS. During Part 1, participants will be randomized to JX 10 (1mg/kg, 3 mg/kg) or placebo. During Part 2,…
Eligibility Snapshot
- : 1. Age ≥ 18 and ≤ 90 years old. 2. Acute ischemic stroke with compatible clinical presentation and symptomatic high grade or complete occlusion of the intracranial internal carotid, M1, M2 or distal branches of the middle cerebral artery (MCA), anterior cerebral artery (ACA), or posterior cerebral artery (PCA). 3. Radiographic evidence of salvageable tissue. 4. Pre-treatment score of NIHSS ≥ 5.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.